Literature DB >> 7620222

Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.

L H Patterson1, M R Craven, G R Fisher, P Teesdale-Spittle.   

Abstract

The DNA binding and cytotoxicity of four intercalating agents, namely bis-alkylamino (-N(CH2)2N(CH3)2) substituted anthraquinone, anthrapyrazole and anthracene, and mono (N(CH2)2N(CH3)2) acridinone, have been compared with their respective aliphatic amine N-oxides -N(CH2)2N+(O-)(CH3)2. The results show that, unlike the intercalators, the N-oxides do not bind to DNA. Molecular modelling illustrates that the delta + nature of the intercalator alkylamino side chains in the protonated form allows for an attractive electrostatic interaction with phosphates of the DNA backbone, whereas the delta- partial charge on the N-oxide makes such an interaction not permissible; indeed, the electrostatic interaction with the DNA phosphates will be repulsive. The N-oxides show little or no cytotoxicity against V79 cells at concentrations equimolar to the IC90 (concentration that inhibits 90% of cell proliferation) of the respective intercalators. However, the cytotoxicity of anthrapyrazole N-oxide against hypoxic V79 cells in the presence of an activating system of S9 liver fraction was enhanced significantly. The results indicate that N-oxides of DNA-affinic agents have potential as bioreductive prodrugs, since they possess low aerobic toxicity but under hypoxic conditions can be metabolised to a potent cytotoxic species presumed to be a DNA-binding tertiary amine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7620222

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  10 in total

Review 1.  Recent developments in the design of bioreductive drugs.

Authors:  W A Denny; W R Wilson; M P Hay
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.

Authors:  W R Wilson; W A Denny; S M Pullen; K M Thompson; A E Li; L H Patterson; H H Lee
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.

Authors:  Clinton R Nishida; Melody Lee; Paul R Ortiz de Montellano
Journal:  Mol Pharmacol       Date:  2010-06-21       Impact factor: 4.436

4.  Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase.

Authors:  Clinton R Nishida; Paul R Ortiz de Montellano
Journal:  J Med Chem       Date:  2008-08-06       Impact factor: 7.446

5.  Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.

Authors:  L H Patterson; S R McKeown; K Ruparelia; J A Double; M C Bibby; S Cole; I J Stratford
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

6.  Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data.

Authors:  L T Baxter; R K Jain
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

7.  DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.

Authors:  M V Hejmadi; S R McKeown; O P Friery; I A McIntyre; L H Patterson; D G Hirst
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

Review 8.  Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

Authors:  Christopher P Guise; Alexandra M Mowday; Amir Ashoorzadeh; Ran Yuan; Wan-Hua Lin; Dong-Hai Wu; Jeff B Smaill; Adam V Patterson; Ke Ding
Journal:  Chin J Cancer       Date:  2013-07-12

Review 9.  ABC transporters in CSCs membranes as a novel target for treating tumor relapse.

Authors:  Laura Zinzi; Marialessandra Contino; Mariangela Cantore; Elena Capparelli; Marcello Leopoldo; Nicola A Colabufo
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

10.  Biological evaluation of the toxicity and the cell cycle interruption by some benzimidazole derivatives.

Authors:  Katarzyna Błaszczak-Świątkiewicz; Joanna Sikora; Jacek Szymański; Marian Danilewicz; Elżbieta Mikiciuk-Olasik
Journal:  Tumour Biol       Date:  2016-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.